Spyre Therapeutics files $500M mixed securities shelf
PremiumThe FlySpyre Therapeutics files $500M mixed securities shelf
2M ago
Wedbush bullish on Spyre Therapeutics, initiates with an Outperform
Premium
The Fly
Wedbush bullish on Spyre Therapeutics, initiates with an Outperform
2M ago
Spyre Therapeutics initiated with an Outperform at Wedbush
Premium
The Fly
Spyre Therapeutics initiated with an Outperform at Wedbush
2M ago
Spyre Therapeutics doses first patients in Phase 1 trial of bowel disease drug
PremiumThe FlySpyre Therapeutics doses first patients in Phase 1 trial of bowel disease drug
5M ago
Spyre Therapeutics Announces Updated Share Structure
Premium
Company Announcements
Spyre Therapeutics Announces Updated Share Structure
5M ago
Spyre Therapeutics Expands Portfolio and Strengthens Leadership
Premium
Company Announcements
Spyre Therapeutics Expands Portfolio and Strengthens Leadership
6M ago
Spyre Therapeutics files to sell 33.36M shares of common stock for holders
PremiumThe FlySpyre Therapeutics files to sell 33.36M shares of common stock for holders
7M ago
Spyre Therapeutics price target raised to $54 from $36 at Stifel
Premium
The Fly
Spyre Therapeutics price target raised to $54 from $36 at Stifel
7M ago
Spyre Therapeutics Secures $180M in Strategic Financial Move
Premium
Company Announcements
Spyre Therapeutics Secures $180M in Strategic Financial Move
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100